163 related articles for article (PubMed ID: 37449387)
1. Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events.
Kilickap S; Ak S; Dursun OU; Sendur MA; Karadurmus N; Demirci U
Future Oncol; 2023 Sep; 19(29):2003-2012. PubMed ID: 37449387
[TBL] [Abstract][Full Text] [Related]
2. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
3. Clinical Management of Adverse Events Associated with Lorlatinib.
Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in the Management of Adverse Events Associated with Lorlatinib.
Liao D; Zhang J; Yan T; Chen S; Li W; Shangguan D; She Z
Onco Targets Ther; 2023; 16():731-738. PubMed ID: 37694103
[TBL] [Abstract][Full Text] [Related]
5. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ; Bauer TM; Mok TSK; Liu G; Mazieres J; de Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
Lancet Respir Med; 2023 Apr; 11(4):354-366. PubMed ID: 36535300
[TBL] [Abstract][Full Text] [Related]
7. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
8. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.
Yun KM; Bazhenova LA
Cancer Manag Res; 2022; 14():843-850. PubMed ID: 35250311
[TBL] [Abstract][Full Text] [Related]
9. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date.
Akamine T; Toyokawa G; Tagawa T; Seto T
Onco Targets Ther; 2018; 11():5093-5101. PubMed ID: 30174447
[TBL] [Abstract][Full Text] [Related]
11. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
Soo RA; Huat Tan E; Hayashi H; Seto T; Lin CC; Ou SI; Kim DW; Liu G; Abbattista A; Martini JF; Hooi Wong C; Toffalorio F; Solomon BJ
Lung Cancer; 2022 Jul; 169():67-76. PubMed ID: 35660971
[TBL] [Abstract][Full Text] [Related]
13. Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
Reed M; Rosales AS; Chioda MD; Parker L; Devgan G; Kettle J
Adv Ther; 2020 Jun; 37(6):3019-3030. PubMed ID: 32399810
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report.
Nakashima K; Demura Y; Kurokawa K; Takeda T; Jikuya N; Oi M; Tada T; Akai M; Ishizuka T
Medicine (Baltimore); 2021 Oct; 100(39):e27385. PubMed ID: 34596160
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
[TBL] [Abstract][Full Text] [Related]
16. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and clinical properties of lorlatinib in the treatment of
El Darsa H; Abdel-Rahman O; Sangha R
Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
[TBL] [Abstract][Full Text] [Related]
19. Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.
Rupp M; Fanton-Aita F; Snow S; Wheatley-Price P; Melosky B; Juergens RA; Chu Q; Blais N; Banerji S; Ng R; Khoudigian S; Sharma A; On PV; Liu G
Curr Oncol; 2023 Jul; 30(7):6559-6574. PubMed ID: 37504341
[TBL] [Abstract][Full Text] [Related]
20. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
Bauer TM; Shaw AT; Johnson ML; Navarro A; Gainor JF; Thurm H; Pithavala YK; Abbattista A; Peltz G; Felip E
Target Oncol; 2020 Feb; 15(1):55-65. PubMed ID: 32060867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
